Written Question · S4W-10963 · Session 4
In light of the fines issued in the United States to pharmaceutical companies for promoting medicines for uses or age groups not in the lic…
The question
To ask the Scottish Government, in light of the fines issued in the United States to pharmaceutical companies for promoting medicines for uses or age groups not in the licence granted in the EU, what consideration it has given to requiring the collection and collation of data related to off-licence prescribing.
The answer
The advertising and promotion of medicines in the UK, as well as medicine safety issues, are subject matters of the Human Medicines Regulations 2012 and are currently reserved issues.
The promotion of a medicine for use outside the terms of its marketing authorisation is prohibited. Details are available in the UK Medicines and Healthcare products Regulatory Agency (MHRA) guidance, The Blue Guide which is available at: http://www.mhra.gov.uk/home/groups/pl-a/documents/publication/con2022589.pdf
The MHRA is also the UK wide licensing authority responsible for ensuring the safety, quality and efficacy of all UK licensed medicines. Side effects to medicines, including those relating to off-licence use, are monitored by the MHRA via the yellow card scheme.
Decisions on whether or not to prescribe a licensed medicinal product for use outside the terms of the marketing authorisation are for the clinical judgement of the prescriber concerned involving full consultation with the patient. There are currently no plans to introduce the routine collection and collation of data related to off licence prescribing.
The promotion of a medicine for use outside the terms of its marketing authorisation is prohibited. Details are available in the UK Medicines and Healthcare products Regulatory Agency (MHRA) guidance, The Blue Guide which is available at: http://www.mhra.gov.uk/home/groups/pl-a/documents/publication/con2022589.pdf
The MHRA is also the UK wide licensing authority responsible for ensuring the safety, quality and efficacy of all UK licensed medicines. Side effects to medicines, including those relating to off-licence use, are monitored by the MHRA via the yellow card scheme.
Decisions on whether or not to prescribe a licensed medicinal product for use outside the terms of the marketing authorisation are for the clinical judgement of the prescriber concerned involving full consultation with the patient. There are currently no plans to introduce the routine collection and collation of data related to off licence prescribing.
In the Official Report
No contribution in the Official Report cites S4W-10963 by reference.